Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, Shen Y, Mulligan SP, Casan J, Blombery P, Tam CS, Roberts AW, Seymour JF, Thompson PA, Anderson MA.
Lew TE, et al. Among authors: seymour jf.
Blood Adv. 2024 Mar 26;8(6):1439-1443. doi: 10.1182/bloodadvances.2023011327.
Blood Adv. 2024.
PMID: 38231032
Free PMC article.
No abstract available.